Clinical Trials · NCT07253285
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
- Phase
- Phase 3
- Recruitment status
- Recruiting
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 460
- Start date
- Jan 2026
- Locations
- 119 sites, 26 countries
- Primary endpoint
- Relative change in body mass index (BMI)